From the Department of Brain & Neurosciences (H.N., K.K., A.H., K.M., H.S.), Tokyo Metropolitan Institute of Medical Science; Department of Neuropediatrics (S.K.), Tokyo Metropolitan Neurological Hospital; Department of Pediatrics (J.-i.T.), Tokyo Women's Medical University Yachiyo Medical Center, Chiba; and Department of Pediatrics (A.O.), Aichi Medical University, Japan.
Neurology. 2021 Apr 20;96(16):e2070-e2077. doi: 10.1212/WNL.0000000000011789. Epub 2021 Mar 2.
To evaluate the validity of the 2016 clinical diagnostic criteria proposed for probable anti-NMDA receptor (NMDAR) encephalitis in children, we tested the criteria in a Japanese pediatric cohort.
We retrospectively reviewed clinical information of patients with neurologic symptoms whose CSF was analyzed for NMDAR antibodies (NMDAR-Abs) in our laboratory from January 1, 2015, to March 31, 2019.
Overall, 137 cases were included. Of the 41 cases diagnosed as probable anti-NMDAR encephalitis (criteria-positive) according to the 2016 criteria, 13 were positive and 28 were negative for anti-NMDAR-Abs. Of the 96 criteria-negative cases, 3 were positive and 93 were negative for anti-NMDAR-Abs. The sensitivity of the criteria was 81.2%, specificity was 76.9%, positive predictive value (PPV) was 31.7%, and negative predictive value was 96.9%. Compared with the true-positive group, the false-positive group contained more male than female patients (male:female, 4:9 in the true-positive vs 19:9 in the false-positive group, = 0.0425). The majority of the cases with false-positive diagnoses were associated with neurologic autoimmunity.
The clinical diagnostic criteria are reliable for deciding to start immunomodulatory therapy in the criteria-positive cases. Low PPV may be caused by a lower prevalence of NMDAR encephalitis or lower level of suspicion for encephalitis in the pediatric population. Physicians should therefore continue differential diagnosis, focusing especially on other forms of encephalitis.
This study provides Class IV evidence that the proposed diagnostic criteria for anti-NMDAR encephalitis in children has a sensitivity of 81.2% and a specificity of 76.9%.
为了评估 2016 年提出的用于儿童抗 NMDA 受体(NMDAR)脑炎的可能诊断标准的有效性,我们在日本儿科队列中对该标准进行了测试。
我们回顾性分析了自 2015 年 1 月 1 日至 2019 年 3 月 31 日期间,在我们实验室进行 NMDA 受体抗体(NMDAR-Abs)检测的神经症状患者的临床信息。
总体上,纳入了 137 例病例。根据 2016 年的标准,41 例被诊断为可能的抗 NMDAR 脑炎(标准阳性),其中 13 例抗 NMDAR-Abs 阳性,28 例阴性;96 例标准阴性病例中,3 例抗 NMDAR-Abs 阳性,93 例阴性。该标准的敏感性为 81.2%,特异性为 76.9%,阳性预测值(PPV)为 31.7%,阴性预测值为 96.9%。与真阳性组相比,假阳性组中男性多于女性(真阳性组:男/女为 4/9,假阳性组为 19/9,=0.0425)。大多数假阳性诊断的病例与神经自身免疫有关。
该临床诊断标准可靠,适用于决定对标准阳性病例开始免疫调节治疗。低 PPV 可能是由于 NMDAR 脑炎的患病率较低,或儿科人群对脑炎的怀疑程度较低所致。因此,医生应继续进行鉴别诊断,尤其要关注其他形式的脑炎。
本研究提供了 IV 级证据,表明用于儿童抗 NMDAR 脑炎的诊断标准具有 81.2%的敏感性和 76.9%的特异性。